Descriptor
| Measures (Individuals) | 2 |
| Psychiatry | 2 |
| Behavior Disorders | 1 |
| Behavior Problems | 1 |
| Check Lists | 1 |
| Child Behavior | 1 |
| Drug Therapy | 1 |
| Intelligence | 1 |
| Outcomes of Treatment | 1 |
| Pervasive Developmental… | 1 |
| Pharmacology | 1 |
| More ▼ | |
Source
| Journal of the American… | 2 |
Author
Publication Type
| Journal Articles | 2 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
What Works Clearinghouse Rating
Peer reviewedOwley, Thomas; Walton, Laura; Salt, Jeff; Guter, Stephen J., Jr.; Winnega, Marrea; Leventhal, Bennett L.; Cook, Edwin H., Jr. – Journal of the American Academy of Child and Adolescent Psychiatry, 2005
Objective: To assess the effect of escitalopram in the treatment of pervasive developmental disorders (PDDs). Method: This 10-week study had a forced titration, open-label design. Twenty-eight subjects (mean age 125.1 [+ or -] 33.5 months) with a PDD received escitalopram at a dose that increased weekly to a maximum dose of 20 mg as tolerated. The…
Descriptors: Measures (Individuals), Psychiatry, Drug Therapy, Pervasive Developmental Disorders
Peer reviewedCroonenberghs, Jan; Fegert, Joerg M.; Findling, Robert L.; de Smedt, Goedele; van Dongen, Stefan – Journal of the American Academy of Child and Adolescent Psychiatry, 2005
Objective: To determine the long-term safety and effectiveness of risperidone for severe disruptive behaviors in children. Method: A multisite, 1-year, open-label study of patients aged 5 to 14 years with disruptive behaviors and subaverage intelligence was conducted. Results: Seventy-three percent of the 504 patients enrolled completed the study.…
Descriptors: Social Behavior, Psychiatry, Pharmacology, Child Behavior
